share_log

European Union Looks To Buy 1.8B Pfizer-BioNTech COVID-19 Vaccine Doses From 2022: Reuters

European Union Looks To Buy 1.8B Pfizer-BioNTech COVID-19 Vaccine Doses From 2022: Reuters

欧盟希望从2022年开始购买18亿剂辉瑞-生物科技新冠肺炎疫苗:路透社
Benzinga Real-time News ·  2021/04/10 02:13
  • The European Commission is reportedly seeking EU governments’ approval to get into talks with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to purchase up to 1.8 billion doses of their COVID-19 vaccines to be delivered in 2022 and 2023, Reuters reported.
  • Earlier today, German daily Die Welt reported that the Commission was to sign contracts shortly to buy up to 1.8 billion doses but did not say with which company.
  • A Commission spokesman confirmed plans to buy the additional doses, of which half would be optional.
  • “If provided the opportunity, Pfizer and BioNTech are prepared to supply Europe with hundreds of millions of doses of COVID vaccines in 2022 and 2023 produced in our manufacturing facilities in Europe,” a Pfizer spokesman said.
  • Both the companies have already said that they can produce more than 3 billion doses of vaccine in 2022.
  • According to another Reuters report, Australia has doubled its order of the PFE COVID-19 vaccine, Prime Minister Scott Morrison said, as the country raced to rebuild its vaccination program after concerns about blood clot risks from AstraZeneca Plc (NASDAQ: AZN) vaccine.
  • Australia based its vaccination program primarily on an AstraZeneca shot until late Thursday, with an order for 50 million doses.
  • But Australia has now joined a host of countries in restricting the use of the AZN vaccine. The Australian authorities now recommend that the country’s nearly 12 million people aged under 50 should take the Pfizer product instead.
  • As a result, Australia has doubled an earlier Pfizer order to 40 million shots, which would be delivered by the end of the year.
  • The policy change to use the Pfizer vaccine effectively ends plans to have the entire population vaccinated by the end of October.
  • Price Action: JNJ shares are down 1.8% at $159.95, while Pfizer shares are up 1.10% at $36.36 during market trading hours on the last check Friday.
  • 据报道,欧盟委员会正在寻求欧盟各国政府的批准,以便与欧盟展开谈判辉瑞公司(纽约证券交易所股票代码:PFE)和BioNTech SE据路透社报道,纳斯达克股票代码:BNTX)将购买多达18亿剂新冠肺炎疫苗,将于2022年和2023年交付。
  • 今天早些时候,德国日报Die Welt报道称,欧盟委员会不久将签署合同,购买多达18亿剂疫苗,但没有透露与哪家公司。
  • 欧盟委员会的一位发言人证实了购买额外剂量的计划,其中一半将是可选的。
  • 辉瑞的一位发言人说:“如果有机会,辉瑞和BioNTech准备在2022年和2023年向欧洲供应数亿剂由我们在欧洲的制造设施生产的COVID疫苗。”
  • 两家公司已经表示,他们在2022年可以生产超过30亿剂疫苗。
  • 根据路透社的另一篇报道,澳大利亚总理斯科特·莫里森表示,澳大利亚已经将PFE新冠肺炎疫苗的订单增加了一倍,因为在担心血液凝块风险之后,澳大利亚正在竞相重建其疫苗接种计划。阿斯利康(AstraZeneca Plc)(纳斯达克市场代码:AZN)疫苗。
  • 澳大利亚的疫苗接种计划主要是基于阿斯利康(AstraZeneca)的疫苗注射,直到周四晚些时候,已经订购了5000万剂。
  • 但澳大利亚现在加入了许多国家的行列,限制AZN疫苗的使用。澳大利亚当局现在建议该国近1200万年龄在50岁以下的人转而服用辉瑞产品。
  • 因此,澳大利亚将辉瑞早些时候的订单翻了一番,达到4000万针,将在今年年底前交付。
  • 使用辉瑞疫苗的政策变化实际上结束了在10月底之前让所有人接种疫苗的计划。
  • 价格行动:摩根大通股价下跌1.8%,至159.95美元,辉瑞股价在周五最后一次交易时段上涨1.10%,至36.36美元。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发